ABIVAX Société Anonyme Management

Management criteria checks 2/4

ABIVAX Société Anonyme's CEO is Marc M. de Garidel, appointed in May 2023, has a tenure of 1.42 years. total yearly compensation is €793.97K, comprised of 45.3% salary and 54.7% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth $383.78K. The average tenure of the management team and the board of directors is 1.3 years and 3.2 years respectively.

Key information

Marc M. de Garidel

Chief executive officer

€794.0k

Total compensation

CEO salary percentage	45.3%
CEO tenure	1.4yrs
CEO ownership	0.06%
Management average tenure	1.3yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Marc M. de Garidel's remuneration changed compared to ABIVAX Société Anonyme's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-€177m
Mar 31 2024	n/a	n/a	-€163m
Dec 31 2023	€794k	€359k	-€148m

Compensation vs Market: Marc M.'s total compensation ($USD857.05K) is below average for companies of similar size in the US market ($USD3.21M).

Compensation vs Earnings: Insufficient data to compare Marc M.'s compensation with company performance.

CEO

Marc M. de Garidel (66 yo)

1.4yrs

Tenure

€793,971

Compensation

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He serves as CEO at ABIVAX Société Anonyme since May 5, 2023 amd serves as its Director. He had been its Interim Chair...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% $ 383.8k
Philippe Pouletty	Founder & Director	no data	€35.00k	0.43% $ 2.8m
Didier Blondel	EVP, CFO & Board Secretary	7.8yrs	no data	0.00059% $ 3.8k
Didier Scherrer	Chief Scientific Officer	1.2yrs	no data	0.057% $ 359.9k
Patrick Malloy	Senior Vice President of Investor Relations	1.2yrs	no data	no data
Ida Hatoum	Chief People & Compliance Officer	1.3yrs	no data	no data
Pierre Courteille	Chief Business Officer	no data	no data	0% $ 0
Jerome Denis	Executive Vice President of Process Development & Manufacturing	1.1yrs	no data	no data
Michael Ferguson	Chief Commercial Officer	1.5yrs	no data	no data
Ana Sharma	VP & Global Head of Quality	less than a year	no data	no data
Hema Keshava	Senior Vice President of Finance	no data	no data	no data
Chris Rabbat	VP & Global Head of Medical Affairs	no data	no data	no data

1.3yrs

Average Tenure

55yo

Average Age

Experienced Management: AAVX.F's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Marc M. de Garidel	CEO & Director	1.4yrs	€793.97k	0.060% $ 383.8k
Philippe Pouletty	Founder & Director	10.8yrs	€35.00k	0.43% $ 2.8m
Sylvie Gregoire	Chair of the Board	less than a year	no data	no data
Christian Trepo	Member of Scientific Advisory Board	no data	no data	no data
Lawrence Stanberry	Member of Scientific Advisory Board	no data	no data	no data
Troy Ignelzi	Independent Director	1.3yrs	€44.33k	no data
Christoph Huber	Member of Scientific Advisory Board	no data	no data	no data
Claude Bertrand	Member of Scientific Advisory Board	5yrs	€4.94k	no data
Luc Teyton	Member of Scientific Advisory Board	no data	no data	no data
June Lee	Independent Director	1.3yrs	€35.24k	no data
Corinna Bonsen-Thomas	Independent Non-Executive Director	7.3yrs	€135.16k	0% $ 0
Ian McGowan	Chairman of Scientific Advisory Board	6.3yrs	no data	no data

3.2yrs

Average Tenure

63.5yo

Average Age

Experienced Board: AAVX.F's board of directors are considered experienced (3.2 years average tenure).

ABIVAX Société Anonyme Management

Management criteria checks 2/4

Key information

Recent management updates

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age